Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)

NCT06230822 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: VUM02 Injection

Sponsor

Wuhan Optics Valley Vcanbiopharma Co., Ltd.